SCHEMBL4074405

SCHEMBL4074405

Brc1ccc2cc(SSc3ccc4cc(Br)ccc4c3)ccc2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 3/20 0.56
TSHR P16473 2/20 0.52
CYP3A4 P08684 1/20 0.52
ALOX15 P16050 1/20 0.52
HIF1A Q16665 1/20 0.52
HSD17B10 Q99714 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
KDM4E B2RXH2 1/20 0.52
MEN1 O00255 1/20 0.52
ALDH1A1 P00352 1/20 0.52
MAPT P10636 1/20 0.52
KMT2A Q03164 1/20 0.52
NCEH1 Q6PIU2 1/20 0.41
BACE1 P56817 2/20 0.40
CYP11B1 P15538 1/20 0.38
CYP11B2 P19099 1/20 0.38
AHR P35869 3/20 0.38
NR4A2 P43354 1/20 0.38
LMNA P02545 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL192166 0.83 CYP2A6 (0.77) CYP2A6ALOX15TDP1KDM4EMEN1
SCHEMBL29353067 0.83 CYP2A6 (0.77) CYP2A6ALOX15TDP1KDM4EMEN1
SCHEMBL5751035 0.80 CYP2A6 (0.52) CYP2A6KDM4EMEN1ALDH1A1MAPT
SCHEMBL9566139 0.78 CYP2A6 (0.62) CYP2A6TSHRALOX15TDP1KDM4E
SCHEMBL23312077 0.77 CYP2A6 (0.68) CYP2A6ALOX15KDM4EMEN1ALDH1A1
SCHEMBL17849089 0.77 CYP2A6 (0.68) CYP2A6ALOX15KDM4EMEN1ALDH1A1
SCHEMBL17849092 0.77 CYP2A6 (0.68) CYP2A6ALOX15KDM4EMEN1ALDH1A1
SCHEMBL148642 0.77 CYP2A6 (0.68) CYP2A6ALOX15KDM4EMEN1ALDH1A1
SCHEMBL13153611 0.77 CYP2A6 (0.68) CYP2A6ALOX15KDM4EMEN1ALDH1A1
SCHEMBL29427549 0.77 CYP2A6 (0.68) CYP2A6ALOX15KDM4EMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7592456-B2 Arylsulfonylnaphthalene derivatives as 5HT2A antagonists MERCK SHARP & DOHME LIMITED (GB) 2009-09-22 US disclosed
EP-1824817-B1 ARYLSULFONYLNAPHTHALENE DERIVATIVES AS 5HT2A ANTAGONISTS MERCK SHARP & DOHME (GB) 2009-02-04 EP disclosed
US-20070281952-A1 Arylsulfonylnaphthalene Derivatives As 5Ht2a Antagonists MERCK SHARPE & DOHME LIMITED (GB) 2007-12-06 US disclosed
EP-1824817-A1 ARYLSULFONYLNAPHTHALENE DERIVATIVES AS 5HT2A ANTAGONISTS MERCK SHARP & DOHME LTD. (GB) 2007-08-29 EP disclosed
WO-2006059149-A1 ARYLSULFONYLNAPHTHALENE DERIVATIVES AS 5HT2A ANTAGONISTS MERCK SHARP & DOHME LIMITED (GB) 2006-06-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281952-A1 Arylsulfonylnaphthalene Derivatives As 5Ht2a Antagonists HTR2A, HTR2C, HTR1A CYP2A6 94/4885TSHR 226/4885CYP3A4 415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.